Business Context and Reporting Period
This Form 8-K, filed on February 14, 2014, reports on events occurring on February 12, 2014, involving DanDrit Biotech USA, Inc. (formerly Putnam Hills Corp.). The filing details a reverse merger where the registrant, previously a shell company with no operations, acquired DanDrit Biotech A/S ("DanDrit Denmark"). Following the transaction, DanDrit USA changed its name to DanDrit Biotech USA, Inc., and its sole business is the development of a vaccine for colorectal cancer previously conducted by DanDrit Denmark. For accounting purposes, DanDrit Denmark is treated as the acquirer, and its historical financial statements now represent the registrant's history.
Key Financial Metrics and Capital Structure
The filing does not provide specific revenue, profit, or cash flow figures within the text of this report; such data is incorporated by reference from a separate S-1 Registration Statement. However, the following capital structure and transaction metrics are disclosed:
- Share Exchange: Approximately 97% of DanDrit Denmark's equity interests (3,879,624 shares) were exchanged for 5,814,945 shares of DanDrit USA common stock.
- Maximum Issuance: Up to 6,000,000 shares of DanDrit USA common stock may be issued in total, including shares for non-consenting shareholders.
- Share Cancellation: 4,400,000 shares of the former DanDrit USA common stock were cancelled.
- Related Party Debt: DanDrit Denmark agreed to pay up to $80,000 plus accrued interest to related parties. This payment is contingent on DanDrit USA raising at least $12 million in gross proceeds from a subsequent offering.
- Liquidity Condition: If the $12 million minimum offering amount is not raised, the $80,000 debt remains outstanding and is payable one year after the offering closes or terminates.
Material Changes Versus Prior Period
The company underwent a fundamental transformation from a shell entity to an operating biotechnology firm:
- Business Operations: Transitioned from no trade or business to developing a colorectal cancer vaccine.
- Management and Board: Former sole officer/director Samir Masri resigned. New leadership includes Dr. Eric Leire (CEO/President), Robert E. Wolfe (CFO), and a reconstituted board including N.E. Nielsen, Dr. Jacob Rosenberg, and Aldo Petersen.
- Corporate Identity: The company name changed from Putnam Hills Corp. to DanDrit Biotech USA, Inc.
- Fiscal Year: The fiscal year-end was changed from March 31 to December 31.
- Shell Status: The company is no longer classified as a shell corporation.
Guidance, Outlook, and Risks
The filing contains forward-looking statements regarding the anticipated success of the vaccine development and future financial performance, which are subject to significant risks and uncertainties. Key contingencies and risks include:
- Capital Raise Contingency: The repayment of the $80,000 related-party loan is contingent on raising a minimum of $12 million in gross proceeds. Failure to raise this amount delays repayment but does not eliminate the debt.
- Regulatory and Development Risks: As a biotech firm, the company faces risks related to the development and regulatory approval of its vaccine candidate.
- Accounting Treatment: The transaction is treated as a reverse acquisition, meaning the historical financials reflect DanDrit Denmark, not the former shell company.
Investor Verification Checklist
- Verify the status of the planned $12 million offering and whether the minimum amount has been raised to trigger the $80,000 debt repayment.
- Review the S-1 Registration Statement (filed February 14, 2014) for the actual audited and unaudited financial statements of DanDrit Denmark, as they are not included in this 8-K text.
- Confirm the pro forma financial information to understand the combined capital structure post-merger.
- Assess the progress of the colorectal cancer vaccine development and any recent regulatory milestones.
- Review the "Risk Factors" section of the S-1 for specific details on the uncertainties facing the new management and business model.